Sipeng Technology Secures Tens of Millions in Pre-A+ Funding to Accelerate High-Performance Bio-Based Materials and Next-Gen Carbon Feedstock Innovation

VCBeat has learned that Shanghai Sipeng Technology Co., Ltd. (hereinafter referred to as “Sipeng Technology”) announced the completion of its Pre-A+ financing round, amounting to tens of millions of yuan. This round of financing was led byShanghai State Investment Futeng CapitalInvestment,Xiqiao CapitalServing as the exclusive financial advisor. The funds raised will be used to accelerate the commercialization of bio-based material products and the construction of a third-generation carbon source biomanufacturing platform.

SiPeng Technology leverages its intelligent bio-manufacturing platform and high-performance material application development platform to dedicate itself to the R&D and production of bio-based products with global competitiveness. In terms of the bio-manufacturing platform, the company has broken the monopoly of overseas technologies, having alreadyCompleted mass production validation for multiple bio-based polyols/acids, in product fermentation concentration, costs, and other aspects are all at the international leading level; bio-basedMaterial ApplicationsIn terms of development, the company possesses outstanding capabilities in the application development of bio-based materials, laying a solid foundation for the multi-scenario application of bio-based products. Its related products and services have been integrated into the supply chains of numerous well-known domestic and international enterprises.

Figure: The Company and Its Partners at the 29th China Beauty Expo

In terms of carbon source iteration,Recently, the company announced a collaboration with the Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences, to jointly advance the industrialization of bio-based material monomers using methanol as a feedstock.SiPeng Technology will, on the basis of the industrial implementation of its first-generation and second-generation carbon source products, lay out the utilization of third-generation carbon sources using C1 compounds such as methanol and carbon dioxide as raw materials,Breakthrough in Traditional Biomanufacturing’s Dependence on Food-Based Carbon Sources, Significantly Reducing Biomanufacturing Costs.

Figure: The Company and Its Partners Reach a Major Collaboration on Carbon Source Iteration

Shanghai State Investment Futeng CapitalIn the field of synthetic biology, short-term success hinges on technology, while long-term viability depends on commercialization. Investment targets must not only be capable of product development but also achieve scaled sales. The company has accumulated decades of basic research experience in synthetic biology, and its founders and team have a proven track record of successful industrialization. Its pipeline in non-grain-based intelligent bio-manufacturing and low-carbon/negative-carbon intelligent bio-manufacturing addresses industrial demands while aligning with the goals of “carbon peaking and carbon neutrality.” We are highly optimistic about the company’s future prospects. It is an honor that the SJTU Technology Source Fund, co-managed by us and Hanyuan Asset, has the opportunity to support Sipeng. We look forward to the company truly demonstrating the negative-carbon, economic, and sustainable advantages of synthetic biology.

Yuan Zipeng, Assistant to the Chairman and Vice President of Si Peng TechnologyIt indicates that the large-scale application of bio-based materials is on the verge of an industrial boom, with major brand enterprises extensively seeking new products that offer both performance and cost advantages. Sifeng Technology will remain market-demand oriented, focusing on providing customers with cost-effective bio-based material solutions, and is committed to becoming a global leader in the bio-based materials industry.

Shanghai State-owned Investment Futeng Capital was established in January 2022. It was jointly founded by Shanghai State-owned Investment Company as the primary sponsor, together with leading industrial groups, investment institutions, and management teams including Lingang Group, SAIC Motor, CATL, and Bilibili. The company has a registered capital of RMB 100 million, currently manages a total asset scale of approximately RMB 30 billion, and has made external investments exceeding RMB 10 billion.

As a market-oriented fund manager, Shanghai State-owned Investment Futeng Capital leverages its PSD full-product-line strategy to comprehensively support the development of Shanghai’s key industries. Through state-owned capital fund-of-funds, it optimizes the allocation of state-owned assets, supports the commercialization of scientific and technological achievements, and fosters collaboration with industrial leaders’ corporate venture capital (CVC) arms. Via S funds, it mobilizes social capital and enhances long-term, patient investment continuity. Through its direct investment fund cluster, it amplifies the influence of state-owned capital and focuses on advancing Shanghai’s three leading pioneer industries.

Xiqiao Capital is an emerging boutique investment bank specializing in the healthcare and hard-tech sectors. Its team members have cultivated deep expertise over many years across investment banking, investing, and industry, boasting extensive resources within the industrial ecosystem. Founded with the mission of building a professional and dedicated bridge between enterprises and the capital markets, the firm provides diversified financial and strategic advisory services, including but not limited to equity financing, mergers and acquisitions, and cross-border transactions.